MacroGenics, Inc. (MGNX) Stock
Fundamentals
Latest news
About MacroGenics, Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Eric Blasius Risser | CEO, President & Director | 1973 |
| Mr. James Karrels | Senior VP & CFO | 1967 |
| Dr. Ezio Bonvini M.D. | Senior VP of Research & Chief Scientific Officer | 1954 |
| Dr. Araba Lamouse-Smith Ph.D. | Vice President of Technical Operations | — |
| Mr. Jeffrey Stuart Peters J.D. | Senior VP, Corporate Secretary, General Counsel & Corporate Compliance Officer | 1971 |
| Mr. Steve Harig | Senior Vice President of Human Resources | — |
| Mr. Harish Krishnaswamy | Senior Vice President of Business Development & Portfolio Planning | — |
| Dr. Frank George Perabo FEBU, M.D., Ph.D. | Vice President & Interim Head of Clinical Development | 1964 |
| Ms. Beth Smith | VP, Controller & Treasurer | 1968 |



